Cargando…

Development of co-processed excipients in the design and evaluation of atorvastatin calcium tablets by direct compression method

INTRODUCTION: Co-processed excipients were prepared to improve the process ability and efficacy of commonly used excipients and to impart multi-functional qualities to the excipients and hence that the tablets with the desired attributes can be produced. In this study, acacia and calcium carbonate (...

Descripción completa

Detalles Bibliográficos
Autores principales: Pusapati, Ravi Teja, Kumar, MVR Kalyan, Rapeti, Siva Satyanandam, Murthy, TEGK
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4083533/
https://www.ncbi.nlm.nih.gov/pubmed/25006555
http://dx.doi.org/10.4103/2230-973X.133059
_version_ 1782324389801361408
author Pusapati, Ravi Teja
Kumar, MVR Kalyan
Rapeti, Siva Satyanandam
Murthy, TEGK
author_facet Pusapati, Ravi Teja
Kumar, MVR Kalyan
Rapeti, Siva Satyanandam
Murthy, TEGK
author_sort Pusapati, Ravi Teja
collection PubMed
description INTRODUCTION: Co-processed excipients were prepared to improve the process ability and efficacy of commonly used excipients and to impart multi-functional qualities to the excipients and hence that the tablets with the desired attributes can be produced. In this study, acacia and calcium carbonate (CaCO(3)) were used to prepare a co-processing excipient suitable for the preparation of atorvastatin calcium tablets. Acacia is used as binder and CaCO(3) as filler. CaCO(3) also acts as alkalizer and thus suitable to improve the dissolution rate of pH dependent soluble drugs like atorvastatin. MATERIALS AND METHODS: The tablets were prepared by direct compression method and the physical properties of tablets such as hardness, friability and dissolution profiles of tablets were evaluated. Acacia was used in the form of mucilage. Various ratios of the co-processing excipients were formulated by granulation technique and the blend properties were evaluated by their Hausner's ratio and Carr's index values. Based on the Kawakita plots, it was found that the formulation with 3% acacia mucilage (0.9 mg acacia and 26.6 mg of CaCO(3)) showed good fluidity and the formulations with 4% (1.27 mg of acacia and 26.23 mg of CaCO(3)) and 5% acacia mucilage (1.62 mg of acacia and 25.88 mg of CaCO(3)) showed more cohesiveness. The formulations include 1-5% of the acacia mucilage as the binding agent. RESULTS: The granules of formulations with low percentage of acacia mucilage (1% and 2%) failed the test for friability. The granules of the formulations with pure acacia (F(1)) and pure CaCO(3) (F(2)) showed passable flow properties. CONCLUSION: The formulation with 3% acacia mucilage (F(3), 0.9 mg acacia and 26.6 mg of CaCO(3)) showed least dissolution time (<1 min) and is found as the best formulation among the other formulations containing 4% (F(4), 1.27 mg of acacia and 26.23 mg of CaCO(3)) and 5% (F(5), 1.62 mg of acacia and 25.88 mg of CaCO(3)) acacia mucilage.
format Online
Article
Text
id pubmed-4083533
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-40835332014-07-08 Development of co-processed excipients in the design and evaluation of atorvastatin calcium tablets by direct compression method Pusapati, Ravi Teja Kumar, MVR Kalyan Rapeti, Siva Satyanandam Murthy, TEGK Int J Pharm Investig Original Research Article INTRODUCTION: Co-processed excipients were prepared to improve the process ability and efficacy of commonly used excipients and to impart multi-functional qualities to the excipients and hence that the tablets with the desired attributes can be produced. In this study, acacia and calcium carbonate (CaCO(3)) were used to prepare a co-processing excipient suitable for the preparation of atorvastatin calcium tablets. Acacia is used as binder and CaCO(3) as filler. CaCO(3) also acts as alkalizer and thus suitable to improve the dissolution rate of pH dependent soluble drugs like atorvastatin. MATERIALS AND METHODS: The tablets were prepared by direct compression method and the physical properties of tablets such as hardness, friability and dissolution profiles of tablets were evaluated. Acacia was used in the form of mucilage. Various ratios of the co-processing excipients were formulated by granulation technique and the blend properties were evaluated by their Hausner's ratio and Carr's index values. Based on the Kawakita plots, it was found that the formulation with 3% acacia mucilage (0.9 mg acacia and 26.6 mg of CaCO(3)) showed good fluidity and the formulations with 4% (1.27 mg of acacia and 26.23 mg of CaCO(3)) and 5% acacia mucilage (1.62 mg of acacia and 25.88 mg of CaCO(3)) showed more cohesiveness. The formulations include 1-5% of the acacia mucilage as the binding agent. RESULTS: The granules of formulations with low percentage of acacia mucilage (1% and 2%) failed the test for friability. The granules of the formulations with pure acacia (F(1)) and pure CaCO(3) (F(2)) showed passable flow properties. CONCLUSION: The formulation with 3% acacia mucilage (F(3), 0.9 mg acacia and 26.6 mg of CaCO(3)) showed least dissolution time (<1 min) and is found as the best formulation among the other formulations containing 4% (F(4), 1.27 mg of acacia and 26.23 mg of CaCO(3)) and 5% (F(5), 1.62 mg of acacia and 25.88 mg of CaCO(3)) acacia mucilage. Medknow Publications & Media Pvt Ltd 2014 /pmc/articles/PMC4083533/ /pubmed/25006555 http://dx.doi.org/10.4103/2230-973X.133059 Text en Copyright: © International Journal of Pharmaceutical Investigation http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research Article
Pusapati, Ravi Teja
Kumar, MVR Kalyan
Rapeti, Siva Satyanandam
Murthy, TEGK
Development of co-processed excipients in the design and evaluation of atorvastatin calcium tablets by direct compression method
title Development of co-processed excipients in the design and evaluation of atorvastatin calcium tablets by direct compression method
title_full Development of co-processed excipients in the design and evaluation of atorvastatin calcium tablets by direct compression method
title_fullStr Development of co-processed excipients in the design and evaluation of atorvastatin calcium tablets by direct compression method
title_full_unstemmed Development of co-processed excipients in the design and evaluation of atorvastatin calcium tablets by direct compression method
title_short Development of co-processed excipients in the design and evaluation of atorvastatin calcium tablets by direct compression method
title_sort development of co-processed excipients in the design and evaluation of atorvastatin calcium tablets by direct compression method
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4083533/
https://www.ncbi.nlm.nih.gov/pubmed/25006555
http://dx.doi.org/10.4103/2230-973X.133059
work_keys_str_mv AT pusapatiraviteja developmentofcoprocessedexcipientsinthedesignandevaluationofatorvastatincalciumtabletsbydirectcompressionmethod
AT kumarmvrkalyan developmentofcoprocessedexcipientsinthedesignandevaluationofatorvastatincalciumtabletsbydirectcompressionmethod
AT rapetisivasatyanandam developmentofcoprocessedexcipientsinthedesignandevaluationofatorvastatincalciumtabletsbydirectcompressionmethod
AT murthytegk developmentofcoprocessedexcipientsinthedesignandevaluationofatorvastatincalciumtabletsbydirectcompressionmethod